4 results
Using a single formulation of PfPEBS LSP administered at two different doses, one of 5*g and the other one of 30*g, both adjuvanted with aluminium hydroxide, in two immunizations at 28 days interval, to evaluate a) the safety and immunogenicity (…
Primary• To evaluate the safety of using a modified staged treatment algorithm at 3*months following the second placement of AeriSeal foam treatment in subjects with severe emphysema.Secondary• To evaluate lung function, exercise tolerance and,…
Primary:To compare the efficacy of asciminib versus Investigator selected TKI with respect to the proportion of patients that are in Major Molecular Response at Week 48. To compare the efficacy of asciminib versus Investigator selected TKI, within…
Primary:1) Feasibility: Evidence of targeted lung volume reduction (TLVR) on CT scan at 6 weeks and 3 months follow up after endobronchial valve placement.Secondary:2) Safety: The number and type of procedure-related (Serious) Adverse events within…